Neurobo Accounts Payable vs Total Liab Analysis

NRBO Stock

USD 3.78 0.05 1.34%

Neurobo Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Neurobo Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neurobo Pharmaceuticals is a good investment. Please check the relationship between Neurobo Pharmaceuticals Accounts Payable and its Total Liab accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurobo Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.

To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.

Accounts Payable vs Total Liab

Accounts Payable vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neurobo Pharmaceuticals Accounts Payable account and Total Liab. At this time, the significance of the direction appears to have weak relationship.

The correlation between Neurobo Pharmaceuticals' Accounts Payable and Total Liab is 0.34. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Total Liab in the same time period over historical financial statements of Neurobo Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Neurobo Pharmaceuticals' Accounts Payable and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Neurobo Pharmaceuticals are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Accounts Payable i.e., Neurobo Pharmaceuticals' Accounts Payable and Total Liab go up and down completely randomly.

Correlation Coefficient

0.34

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Neurobo Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Neurobo Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Neurobo Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neurobo Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurobo Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.

To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.At this time, Neurobo Pharmaceuticals' Enterprise Value Over EBITDA is very stable compared to the past year. As of the 6th of May 2024, Enterprise Value Multiple is likely to grow to 0.23, while Selling General Administrative is likely to drop 6,392.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	48K	20K	3K	2.9K
Cost Of Revenue	72K	28K	7K	6.7K

Reconciled Depreciation Cost Of Revenue

Neurobo Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Non Currrent Assets Other	Non Current Liabilities Total	Non Current Liabilities Other	Net Tangible Assets
Total Assets		0.26	0.76	0.71	0.19	-0.83	-0.95	-0.83	0.52	1.0	0.07	-0.23	1.0	0.87	0.33	0.83	0.51	0.78	0.28	1.0	-0.04	0.53	-0.83	0.05	0.18	0.43
Short Long Term Debt Total	0.26		-0.2	0.44	-0.52	-0.11	0.01	0.0	0.62	0.25	0.37	0.24	0.25	0.21	-0.26	0.29	0.34	-0.13	0.62	0.25	0.65	0.28	-0.02	0.55	0.44	-0.64
Other Current Liab	0.76	-0.2		0.63	0.4	-0.45	-0.82	-0.62	0.03	0.77	-0.16	-0.17	0.77	0.52	0.32	0.48	0.25	0.74	-0.04	0.77	-0.26	0.3	-0.58	-0.22	-0.08	0.58
Total Current Liabilities	0.71	0.44	0.63		-0.23	-0.33	-0.54	-0.64	0.41	0.71	0.5	0.3	0.71	0.63	0.22	0.73	0.1	0.55	0.56	0.7	0.49	0.39	-0.38	0.33	0.17	0.08
Total Stockholder Equity	0.19	-0.52	0.4	-0.23		-0.16	-0.41	-0.07	-0.11	0.19	-0.6	-0.14	0.19	-0.01	0.26	-0.1	0.36	0.49	-0.89	0.2	-0.91	-0.13	-0.54	-0.96	0.05	0.77
Current Deferred Revenue	-0.83	-0.11	-0.45	-0.33	-0.16		0.81	0.78	-0.63	-0.82	0.07	0.53	-0.82	-0.86	-0.26	-0.76	-0.39	-0.6	-0.23	-0.83	0.2	-0.55	0.84	-0.08	-0.24	-0.4
Net Debt	-0.95	0.01	-0.82	-0.54	-0.41	0.81		0.79	-0.33	-0.95	0.11	0.34	-0.95	-0.78	-0.44	-0.7	-0.56	-0.8	-0.03	-0.95	0.3	-0.41	0.87	0.17	-0.02	-0.62
Retained Earnings	-0.83	0.0	-0.62	-0.64	-0.07	0.78	0.79		-0.46	-0.82	-0.23	0.23	-0.82	-0.93	-0.61	-0.9	-0.11	-0.82	-0.32	-0.82	-0.01	-0.37	0.78	-0.12	-0.14	-0.56
Accounts Payable	0.52	0.62	0.03	0.41	-0.11	-0.63	-0.33	-0.46		0.5	0.11	-0.09	0.5	0.61	-0.01	0.62	0.23	0.34	0.34	0.52	0.15	0.45	-0.59	0.2	0.71	-0.11
Cash	1.0	0.25	0.77	0.71	0.19	-0.82	-0.95	-0.82	0.5		0.05	-0.25	1.0	0.86	0.33	0.82	0.51	0.77	0.27	1.0	-0.05	0.52	-0.83	0.04	0.18	0.43
Non Current Assets Total	0.07	0.37	-0.16	0.5	-0.6	0.07	0.11	-0.23	0.11	0.05		0.69	0.05	0.32	0.06	0.49	-0.21	0.07	0.62	0.05	0.8	0.16	0.15	0.52	-0.2	-0.18
Other Assets	-0.23	0.24	-0.17	0.3	-0.14	0.53	0.34	0.23	-0.09	-0.25	0.69		-0.25	-0.17	-0.16	0.04	-0.15	0.0	0.03	-0.25	0.47	-0.05	0.28	-0.05	-0.11	-0.12
Cash And Short Term Investments	1.0	0.25	0.77	0.71	0.19	-0.82	-0.95	-0.82	0.5	1.0	0.05	-0.25		0.86	0.33	0.82	0.51	0.77	0.27	1.0	-0.05	0.52	-0.83	0.04	0.18	0.43
Common Stock Total Equity	0.87	0.21	0.52	0.63	-0.01	-0.86	-0.78	-0.93	0.61	0.86	0.32	-0.17	0.86		0.41	0.97	0.27	0.78	0.41	0.86	0.11	0.53	-0.79	0.2	0.14	0.4
Common Stock Shares Outstanding	0.33	-0.26	0.32	0.22	0.26	-0.26	-0.44	-0.61	-0.01	0.33	0.06	-0.16	0.33	0.41		0.35	-0.01	0.49	-0.07	0.33	-0.2	-0.5	-0.43	-0.17	-0.03	0.6
Capital Surpluse	0.83	0.29	0.48	0.73	-0.1	-0.76	-0.7	-0.9	0.62	0.82	0.49	0.04	0.82	0.97	0.35		0.2	0.77	0.48	0.82	0.25	0.56	-0.73	0.24	0.16	0.34
Other Current Assets	0.51	0.34	0.25	0.1	0.36	-0.39	-0.56	-0.11	0.23	0.51	-0.21	-0.15	0.51	0.27	-0.01	0.2		0.27	-0.12	0.52	-0.24	0.27	-0.5	-0.21	-0.11	0.1
Other Stockholder Equity	0.78	-0.13	0.74	0.55	0.49	-0.6	-0.8	-0.82	0.34	0.77	0.07	0.0	0.77	0.78	0.49	0.77	0.27		-0.12	0.77	-0.28	0.35	-0.86	-0.36	0.12	0.75
Total Liab	0.28	0.62	-0.04	0.56	-0.89	-0.23	-0.03	-0.32	0.34	0.27	0.62	0.03	0.27	0.41	-0.07	0.48	-0.12	-0.12		0.26	0.87	0.35	0.14	0.96	0.04	-0.54
Total Current Assets	1.0	0.25	0.77	0.7	0.2	-0.83	-0.95	-0.82	0.52	1.0	0.05	-0.25	1.0	0.86	0.33	0.82	0.52	0.77	0.26		-0.06	0.53	-0.84	0.04	0.18	0.43
Short Term Debt	-0.04	0.65	-0.26	0.49	-0.91	0.2	0.3	-0.01	0.15	-0.05	0.8	0.47	-0.05	0.11	-0.2	0.25	-0.24	-0.28	0.87	-0.06		0.17	0.42	0.85	-0.02	-0.66
Common Stock	0.53	0.28	0.3	0.39	-0.13	-0.55	-0.41	-0.37	0.45	0.52	0.16	-0.05	0.52	0.53	-0.5	0.56	0.27	0.35	0.35	0.53	0.17		-0.4	0.23	0.11	-0.01
Non Currrent Assets Other	-0.83	-0.02	-0.58	-0.38	-0.54	0.84	0.87	0.78	-0.59	-0.83	0.15	0.28	-0.83	-0.79	-0.43	-0.73	-0.5	-0.86	0.14	-0.84	0.42	-0.4		0.35	-0.32	-0.67
Non Current Liabilities Total	0.05	0.55	-0.22	0.33	-0.96	-0.08	0.17	-0.12	0.2	0.04	0.52	-0.05	0.04	0.2	-0.17	0.24	-0.21	-0.36	0.96	0.04	0.85	0.23	0.35		-0.03	-0.68
Non Current Liabilities Other	0.18	0.44	-0.08	0.17	0.05	-0.24	-0.02	-0.14	0.71	0.18	-0.2	-0.11	0.18	0.14	-0.03	0.16	-0.11	0.12	0.04	0.18	-0.02	0.11	-0.32	-0.03		-0.1
Net Tangible Assets	0.43	-0.64	0.58	0.08	0.77	-0.4	-0.62	-0.56	-0.11	0.43	-0.18	-0.12	0.43	0.4	0.6	0.34	0.1	0.75	-0.54	0.43	-0.66	-0.01	-0.67	-0.68	-0.1

Click cells to compare fundamentals

Neurobo Pharmaceuticals Account Relationship Matchups

Neurobo Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	14.5M	11.0M	16.8M	33.5M	22.8M	18.4M
Short Long Term Debt Total	116K	94K	71K	203K	182.7K	173.6K
Other Current Liab	1.4M	1.1M	1.3M	11.1M	5.1M	2.6M
Total Current Liabilities	2.1M	3.7M	2.2M	11.8M	6.0M	6.1M
Total Stockholder Equity	12.3M	7.2M	14.6M	21.8M	16.7M	17.5M
Net Debt	(13.8M)	(10.0M)	(16.3M)	(33.4M)	(22.2M)	(21.1M)
Retained Earnings	(36.9M)	(66.5M)	(81.8M)	(95.8M)	(108.3M)	(102.9M)
Accounts Payable	638K	2.6M	830K	708K	821K	1.1M
Cash	13.9M	10.1M	16.4M	33.4M	22.4M	17.8M
Non Current Assets Total	350K	285K	215K	2K	269.0K	220.2K
Cash And Short Term Investments	13.9M	10.1M	16.4M	33.4M	22.4M	17.8M
Common Stock Total Equity	18K	22K	16K	20K	23K	17.9K
Common Stock Shares Outstanding	21.8K	67.6K	96.4K	321.7K	5.1M	5.3M
Liabilities And Stockholders Equity	14.5M	11.0M	16.8M	33.5M	22.8M	18.4M
Capital Surpluse	64.4M	91.9M	49.1M	73.7M	84.8M	59.9M
Other Current Assets	42K	48K	197K	168K	77K	105.8K
Other Stockholder Equity	34.7M	73.7M	96.4M	117.5M	124.9M	69.3M
Total Liab	2.2M	3.8M	2.2M	11.8M	6.1M	5.8M
Total Current Assets	14.1M	10.7M	16.6M	33.5M	22.5M	18.1M
Short Term Debt	22K	24K	26K	67K	60.3K	57.3K
Common Stock	16K	20K	27K	25K	5K	4.8K
Non Currrent Assets Other	740K	350K	130K	21.0K	18.9K	18.0K
Non Current Liabilities Total	94K	70K	45K	708K	136K	129.2K
Net Tangible Assets	(13.3M)	12.3M	7.2M	14.6M	16.8M	17.6M
Net Invested Capital	12.3M	7.2M	14.6M	21.8M	16.7M	16.3M
Net Working Capital	12.0M	7.0M	14.4M	21.7M	16.6M	14.5M
Capital Stock	16K	20K	27K	25K	5K	4.8K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Neurobo Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurobo Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurobo Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurobo Pharmaceuticals Stock:

How To Invest In Neurobo

Details

Is Neurobo Stock a good investment?

Details

What is Neurobo Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurobo Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.

To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.

Note that the Neurobo Pharmaceuticals information on this page should be used as a complementary analysis to other Neurobo Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Complementary Tools for Neurobo Stock analysis

When running Neurobo Pharmaceuticals' price analysis, check to measure Neurobo Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurobo Pharmaceuticals is operating at the current time. Most of Neurobo Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Neurobo Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurobo Pharmaceuticals' price. Additionally, you may evaluate how the addition of Neurobo Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Transaction History View history of all your transactions and understand their impact on performance
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Volatility Analysis Get historical volatility and risk analysis based on latest market data

Is Neurobo Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurobo Pharmaceuticals. If investors know Neurobo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurobo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.46)

Return On Assets

(0.35)

Return On Equity

(0.65)

The market value of Neurobo Pharmaceuticals is measured differently than its book value, which is the value of Neurobo that is recorded on the company's balance sheet. Investors also form their own opinion of Neurobo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Neurobo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurobo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Neurobo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Neurobo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurobo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurobo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Neurobo Accounts Payable vs Total Liab Analysis

Accounts Payable vs Total Liab

Accounts Payable vs Total Liab Correlation Analysis

Correlation Coefficient

Accounts Payable

Total Liab

Neurobo Pharmaceuticals fundamental ratios Correlations

Neurobo Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Neurobo Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Neurobo Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments

Non Current Liabilities Total	- 0.96	Total Stockholder Equity
Total Current Assets	- 0.95	Net Debt
Cash And Short Term Investments	- 0.95	Net Debt
Cash	- 0.95	Net Debt
Net Debt	- 0.95	Total Assets
Common Stock Total Equity	- 0.93	Retained Earnings